From Surf Wiki (app.surf) — the open knowledge base

Glycemic efficacy

Glycemic efficacy refers to the capacity of regulated glycemic levels to produce an effect in people with diabetes and heart disease. According to Zeev Vlodaver, Robert F. Wilson and Daniel J. Garry, "exenatide and liraglutide are synthetic GLP-1 agonists and have demonstrated glycemic efficacy (HbA1c reductions of between 0.7 and 2%) associated with mild weight loss." Glyburide, metformin and rosiglitazone have been assessed as a monotherapy in the durability of glycemic efficacy.

References

(2004). "Diabetes and Cardiovascular Disease: Integrating Science and Clinical Medicine". Lippincott Williams & Wilkins.
(31 January 2012). "Coronary Heart Disease: Clinical, Pathological, Imaging, and Molecular Profiles". Springer.
(26 July 2011). "Textbook of Diabetes". John Wiley & Sons.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

diabetes

Want to explore this topic further?

Ask Mako anything about Glycemic efficacy — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report